177 related articles for article (PubMed ID: 29408532)
21. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
[TBL] [Abstract][Full Text] [Related]
22. An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles.
Yamada Y; Fukuda Y; Harashima H
Mitochondrion; 2015 Sep; 24():50-5. PubMed ID: 26188112
[TBL] [Abstract][Full Text] [Related]
23. [Inhibitory effect of human mitochondria-targeted MPG recombinant on proliferation of human non-small cell lung cancer multidrug-resistant cell line A549/DDP].
Yu SC; Qian GS; Li YY; Lu WZ; Li J; Huang GJ
Ai Zheng; 2006 Apr; 25(4):421-6. PubMed ID: 16613673
[TBL] [Abstract][Full Text] [Related]
24. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
Furukawa R; Yamada Y; Kawamura E; Harashima H
Biomaterials; 2015 Jul; 57():107-15. PubMed ID: 25913255
[TBL] [Abstract][Full Text] [Related]
25. Mitochondria-Targeted Gene Silencing Facilitated by Mito-CPDs.
Lang W; Tan W; Zhou B; Zhuang Y; Zhang B; Jiang L; Yao SQ; Ge J
Chemistry; 2023 May; 29(26):e202204021. PubMed ID: 36806226
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter.
Kawamura E; Yamada Y; Harashima H
Mitochondrion; 2013 Nov; 13(6):610-4. PubMed ID: 24012978
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice.
Yamada Y; Munechika R; Satrialdi ; Kubota F; Sato Y; Sakurai Y; Harashima H
J Pharm Sci; 2020 Aug; 109(8):2493-2500. PubMed ID: 32376272
[TBL] [Abstract][Full Text] [Related]
28. [New therapeutic strategy for mitochondrial diseases].
Goto Y
Rinsho Shinkeigaku; 2008 Nov; 48(11):1016-7. PubMed ID: 19198149
[TBL] [Abstract][Full Text] [Related]
29. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion.
Yamada Y; Akita H; Kamiya H; Kogure K; Yamamoto T; Shinohara Y; Yamashita K; Kobayashi H; Kikuchi H; Harashima H
Biochim Biophys Acta; 2008 Feb; 1778(2):423-32. PubMed ID: 18054323
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases.
Yamada Y; Harashima H
Adv Drug Deliv Rev; 2008; 60(13-14):1439-62. PubMed ID: 18655816
[TBL] [Abstract][Full Text] [Related]
31. Packaging of the Coenzyme Q
Yamada Y; Burger L; Kawamura E; Harashima H
Biol Pharm Bull; 2017; 40(12):2183-2190. PubMed ID: 29199241
[TBL] [Abstract][Full Text] [Related]
32. [Mitochondrial DDS Opens Innovative Pharmaceutics].
Yamada Y
Yakugaku Zasshi; 2016; 136(1):55-62. PubMed ID: 26725668
[TBL] [Abstract][Full Text] [Related]
33. Development of mitochondrial gene replacement therapy.
Khan SM; Bennett JP
J Bioenerg Biomembr; 2004 Aug; 36(4):387-93. PubMed ID: 15377877
[TBL] [Abstract][Full Text] [Related]
34. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.
Yamada Y; Harashima H
Mitochondrion; 2013 Sep; 13(5):526-32. PubMed ID: 23000575
[TBL] [Abstract][Full Text] [Related]
35. Focal arterial transgene expression after local gene delivery.
Ma X; Glover C; Miller H; Goldstein J; O'Brien E
Can J Cardiol; 2001 Aug; 17(8):873-83. PubMed ID: 11521130
[TBL] [Abstract][Full Text] [Related]
36. Multifunctional enveloped nanodevices (MENDs).
Sato Y; Nakamura T; Yamada Y; Akita H; Harashima H
Adv Genet; 2014; 88():139-204. PubMed ID: 25409606
[TBL] [Abstract][Full Text] [Related]
37. Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium.
Abe J; Yamada Y; Takeda A; Harashima H
J Control Release; 2018 Jan; 269():177-188. PubMed ID: 29146241
[TBL] [Abstract][Full Text] [Related]
38. Progress and prospects: gene therapy for mitochondrial DNA disease.
Kyriakouli DS; Boesch P; Taylor RW; Lightowlers RN
Gene Ther; 2008 Jul; 15(14):1017-23. PubMed ID: 18496570
[TBL] [Abstract][Full Text] [Related]
39. Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells.
Abe J; Yamada Y; Harashima H
J Pharm Sci; 2016 Feb; 105(2):734-740. PubMed ID: 26523487
[TBL] [Abstract][Full Text] [Related]
40. Development of a Mitochondrial Targeting Lipid Nanoparticle Encapsulating Berberine.
Hori I; Harashima H; Yamada Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
